Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACC Annual Scientific Session In Brief

This article was originally published in The Gray Sheet

Executive Summary

COMPASS-HF: Remote monitoring with Medtronic's investigational Chronicle implantable hemodynamic monitor (IHM) is associated with 41% fewer heart-failure related hospitalizations compared with optimal medical management alone in the 274-patient, 28-center randomized COMPASS-HF (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure) study. Enrollees had NYHA Class III or IV heart failure and made at least one heart failure-related hospital trip in the last six months. Robert Bourge, MD, University of Alabama-Birmingham, presented the study results at the American College of Cardiology Annual Scientific Session in Orlando March 8...

You may also be interested in...



Cardiology News In Brief

Heart CARE for diabetics: Updated results from Medtronic's 813-patient CARE-HF study finds Medtronic's cardiac resynchronization therapy (CRT) is equally effective for diabetic and nondiabetic heart failure patients. CRT reduced the all-cause mortality rate in diabetic patients by 39%, compared with a 40% reduction in nondiabetics, the firm reported Sept. 3 at the European Society of Cardiology/World Congress of Cardiology 2006 meeting in Barcelona. Overall, Medtronic's InSync CRT products reduced the risk of heart failure death by 45% and sudden cardiac death by 53% in the study, which randomized patients to medical management with and without CRT, with an average follow-up period of about 36 months (1"The Gray Sheet" March 14, 2005, p. 7)...

Cardiology News In Brief

Heart CARE for diabetics: Updated results from Medtronic's 813-patient CARE-HF study finds Medtronic's cardiac resynchronization therapy (CRT) is equally effective for diabetic and nondiabetic heart failure patients. CRT reduced the all-cause mortality rate in diabetic patients by 39%, compared with a 40% reduction in nondiabetics, the firm reported Sept. 3 at the European Society of Cardiology/World Congress of Cardiology 2006 meeting in Barcelona. Overall, Medtronic's InSync CRT products reduced the risk of heart failure death by 45% and sudden cardiac death by 53% in the study, which randomized patients to medical management with and without CRT, with an average follow-up period of about 36 months (1"The Gray Sheet" March 14, 2005, p. 7)...

CRT-D May Reap Higher CE Ratio Than Defibrillation Alone – Annals Editorial

Implantable cardioverter defibrillators with resynchronization (CRT-D) are likely to prove more cost-effective than ICD therapy alone for patients with moderate-to-severe heart failure, according to Stephen Pauker, MD, et al., Tufts University

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel